• +1-646-491-9876
    • +91-20-67278686

    Search

    Premenstrual Syndrome - Pipeline Review, H1 2017

    Premenstrual Syndrome - Pipeline Review, H1 2017

    • Report Code ID: RW0001709452
    • Category Pharmaceuticals
    • No. of Pages 28
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Premenstrual Syndrome - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Premenstrual Syndrome - Pipeline Review, H1 2017, provides an overview of the Premenstrual Syndrome (Women's Health) pipeline landscape.

    Premenstrual syndrome (PMS) is a collection of physical and emotional symptoms related to a woman's menstrual cycle. Premenstrual syndrome has a wide variety of symptoms, including mood swings, tender breasts, food cravings, fatigue, irritability and depression.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Premenstrual Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Premenstrual Syndrome (Women's Health) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Premenstrual Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premenstrual Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 2 and 1 respectively.

    Premenstrual Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Premenstrual Syndrome (Women's Health) .
    - The pipeline guide reviews pipeline therapeutics for Premenstrual Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Premenstrual Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Premenstrual Syndrome (Women's Health) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Premenstrual Syndrome (Women's Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Premenstrual Syndrome (Women's Health) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Premenstrual Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Premenstrual Syndrome - Overview
    Premenstrual Syndrome - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Premenstrual Syndrome - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Premenstrual Syndrome - Companies Involved in Therapeutics Development
    Asarina Pharma AB
    Pherin Pharmaceuticals Inc
    Premenstrual Syndrome - Drug Profiles
    estrogen + progesterone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PH-80PMD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sepranolone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule 1 to Antagonize GABAA Receptor for PMDD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule 2 to Antagonize GABAA Receptor for PMDD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Premenstrual Syndrome - Dormant Projects
    Premenstrual Syndrome - Product Development Milestones
    Featured News & Press Releases
    Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)
    Jun 12, 2014: Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder
    Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood's candidate drug for severe premenstrual symptoms
    May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Premenstrual Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Premenstrual Syndrome - Pipeline by Asarina Pharma AB, H1 2017
    Premenstrual Syndrome - Pipeline by Pherin Pharmaceuticals Inc, H1 2017
    Premenstrual Syndrome - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Premenstrual Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Asarina Pharma AB
    Pherin Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//premenstrual-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//premenstrual-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//premenstrual-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments